Physiogenex is a preclinical CRO providing original and benchmarked animal models of obesity/type 2 diabetes and related co-morbidities: NASH, dyslipidemia, inflammation, diabetic nephropathy and cardiovascular complications, including HFpEF and atherosclerosis.
For >15 years, we have been evaluating the efficacy of our clients' drugs using gold-standard and radio-tracer based experiments in our validated preclinical models. All our preclinical models are validated with clinical benchmarks.
Our customers benefit from our experience in drug development and expertise in metabolic diseases, as demonstrated by our numerous co-publications with our industrial partners.
In 2021, our customers satisfaction score was 9.75 / 10.